Tailored immunotherapy cocktail shows promise for tough stomach cancer
NCT ID NCT04739202
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while others got atezolizumab plus bevacizumab. The goal was to see if tailoring therapy could improve response rates in this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab combined with either Ipatasertib or Bevacizumab
- What this could lead to
- If successful, this approach could lead to more effective, personalized treatment options for advanced gastric cancer patients who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 54 participants, so results may not apply to all patients. The combinations may cause side effects or fail to improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aphm - Hopital La Timone
Marseille, 13385, France
-
Aphp - Hopital Pitie Salpetriere
Paris, 75013, France
-
Aphp - Hopital Saint-Louis
Paris, 75010, France
-
Bordeaux - Hopital Haut-Leveque
Pessac, 33604, France
-
Dijon - Centre Georges-Francois Leclerc
Dijon, 21000, France
-
Hcl - Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Hcl - Hopital Edouard Herriot
Lyon, 69003, France
-
Toulouse - Iuct Rangueil-Larrey
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?